US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% SNDK $1,719.99 ▲+0.00% NVDA $233.95 ▲+0.00% SPCX $158.96 ▲+0.00% AMD $633.91 ▲+0.00% MSTR $160.01 ▲+0.00% ASML $1,867.31 ▲+0.00%
FinancialContent

PepGen Inc. - Common Stock (NQ:PEPG)

2.280 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about PepGen Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
From PepGen Inc.
Via Business Wire
News headline image
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
From PepGen Inc.
Via Business Wire
News headline image
PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program
From PepGen Inc.
Via Business Wire
News headline image
PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
From PepGen Inc.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
From Pomerantz LLP
Via GlobeNewswire
News headline image
PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data
From PepGen Inc.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
From Pomerantz LLP
Via GlobeNewswire
News headline image
PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights
From PepGen Inc.
Via Business Wire
News headline image
PepGen Announces Regulatory Updates on FREEDOM2
From PepGen Inc.
Via Business Wire
News headline image
PepGen to Participate in the Leerink Global Healthcare Conference
From PepGen Inc.
Via Business Wire
News headline image
PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Business and Legal Officer
From PepGen Inc.
Via Business Wire
News headline image
PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer
From PepGen Inc.
Via Business Wire
News headline image
PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Molecule
From PepGen Inc.
Via Business Wire
News headline image
PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
From PepGen Inc.
Via Business Wire
News headline image
PepGen to Participate in Upcoming Investor Conferences
From PepGen Inc.
Via Business Wire
News headline image
PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society
From PepGen Inc.
Via Business Wire
News headline image
PepGen Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
From PepGen Inc.
Via Business Wire
News headline image
PepGen Announces Pricing of $100 Million Public Offering
From PepGen Inc.
Via Business Wire
News headline image
PepGen Announces Proposed Public Offering
From PepGen Inc.
Via Business Wire
News headline image
PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients
From PepGen Inc.
Via Business Wire
News headline image
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
Levi &amp; Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 8, 2025 in PepGen Inc. Lawsuit - PEPG
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 8, 2025 in PepGen Inc. Lawsuit - PEPG
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
PEPGEN (PEPG) FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds PepGen Investors of the August 8th Deadline and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
PepGen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before August 8, 2025 to Discuss Your Rights - PEPG
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
< Previous 1 2 3 4 5 6 7 8 9 Next >